专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08735604B2 Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use 有权
标题翻译：吡咯烷作为胰高血糖素受体拮抗剂，组合物及其使用方法
公开(公告)号：US08735604B2
公开(公告)日：2014-05-27
申请号：US13496236
申请日：2010-09-16
申请人： Eric J. Gilbert , Michael W. Miller , Duane Eugene DeMong , Andrew W. Stamford , William J. Greenlee
发明人： Eric J. Gilbert , Michael W. Miller , Duane Eugene DeMong , Andrew W. Stamford , William J. Greenlee
IPC分类号： C07D207/09 , A61K31/40
CPC分类号： A61K31/40 , C07D207/08 , C07D207/09 , C07D207/48 , C07D207/50
摘要： The present invention relates to compounds of the general formula: (I) wherein ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
摘要翻译：本发明涉及以下通式的化合物：其中环B，R 1，R 2，R 3，Z和L 1彼此独立地并且如本文所定义，包含该化合物的组合物，以及使用的方法该化合物作为胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及与之相关的病症。

2. 发明申请

US20130012493A1 NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE 审中-公开
标题翻译：作为GLUCAGON受体拮抗剂，组合物及其使用方法的新型SPIRO咪达唑仑衍生物
公开(公告)号：US20130012493A1
公开(公告)日：2013-01-10
申请号：US13636276
申请日：2011-03-22
申请人： He Zhao , Ping Chen , Peishan Lin , Peng Dai , Jason Louis Davis , Duane E. DeMong , Michael W. Miller , Xing Dai , Michael K. Wong , Brian J. Lavey , Wensheng Yu , Guowei Zhou , Andrew W. Stamford , Joseph A. Kozlowski , William J. Greenlee
发明人： He Zhao , Ping Chen , Peishan Lin , Peng Dai , Jason Louis Davis , Duane E. DeMong , Michael W. Miller , Xing Dai , Michael K. Wong , Brian J. Lavey , Wensheng Yu , Guowei Zhou , Andrew W. Stamford , Joseph A. Kozlowski , William J. Greenlee
IPC分类号： A61K31/454 , A61P3/10 , C07D403/12 , A61K31/4178 , A61K31/5386 , A61K31/55 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D498/08 , C07D401/14 , C07D403/14
CPC分类号： C07D403/12 , C07D401/04 , C07D401/14 , C07D403/14 , C07D413/04 , C07D413/14 , C07D491/08 , C07D498/08
摘要： The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
摘要翻译：本发明涉及通式（I）的化合物：其中环A，环B，G，R 3，Z，L 1和L 2彼此独立地并且如本文所定义，包含该化合物的组合物，和涉及使用该化合物作为胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及与之有关的病症的方法。

3. 发明申请

US20130012434A1 NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE 审中-公开
标题翻译：作为GLUCAGON受体拮抗剂，组合物及其使用方法的新型SPIRO咪唑烷
公开(公告)号：US20130012434A1
公开(公告)日：2013-01-10
申请号：US13636244
申请日：2011-03-22
申请人： Michael K. Wong , Brian J. Lavey , Wensheng Yu , Joseph A. Kozlowski , Duanc E. DeMong , Xing Dai , Andrew W. Stamford , Michael W. Miller , Guowei Zhou , De-Yi Yang , William J. Greenlee
发明人： Michael K. Wong , Brian J. Lavey , Wensheng Yu , Joseph A. Kozlowski , Duanc E. DeMong , Xing Dai , Andrew W. Stamford , Michael W. Miller , Guowei Zhou , De-Yi Yang , William J. Greenlee
IPC分类号： A61K31/4184 , C07D235/02 , C07D471/10 , A61K31/438 , C07F7/10 , A61K31/695 , C07D491/107 , C07D487/10 , A61K31/4188 , C07D403/14 , A61K31/497 , A61K31/506 , C07D487/04 , A61K31/4985 , A61K38/28 , A61P3/10 , A61K38/17 , A61K38/26 , A61K31/7034 , A61K31/7048 , A61P3/04 , A61P3/06 , A61P9/10 , C07D403/12
CPC分类号： C07D403/12 , C07D233/70 , C07D401/10 , C07D405/10 , C07F7/0812
摘要： The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
摘要翻译：本发明涉及以下通式的化合物：其中环A，环B，R 1，R 3，Z，L 1和L 2彼此独立地并且如本文所定义，包含该化合物的组合物，以及使用该化合物作为胰高血糖素受体拮抗剂，并用于治疗或预防2型糖尿病及与此有关的病症。

4. 发明申请

US20120108505A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE 有权
标题翻译：作为GLUCAGON受体拮抗剂的THIOPHENES，组合物及其使用方法
公开(公告)号：US20120108505A1
公开(公告)日：2012-05-03
申请号：US13377707
申请日：2010-06-10
申请人： Eric J. Gilbert , Michael W. Miller , Andrew W. Stamford , William J. Greenlee
发明人： Eric J. Gilbert , Michael W. Miller , Andrew W. Stamford , William J. Greenlee
IPC分类号： A61K31/4155 , A61K38/28 , A61K38/17 , A61K31/70 , A61K31/7034 , A61K31/7048 , A61P3/10 , A61P3/08 , A61P5/48 , A61P3/04 , A61P3/06 , A61P7/00 , A61P9/10 , A61P1/18 , A61P25/28 , A61P27/02 , A61P13/12 , A61P25/02 , A61P3/00 , C07D409/06
CPC分类号： C07D409/06 , A61K31/4155 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds of the general formula (I): wherein R1, R2, R3, R5, s, and Z are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
摘要翻译：本发明涉及通式（I）的化合物：其中R 1，R 2，R 3，R 5，S和Z彼此独立地选自并且如本文所定义，包括该化合物的组合物，以及使用化合物作为胰高血糖素受体拮抗剂并用于治疗或预防2型糖尿病及其相关病症。

5. 发明授权

US06391865B1 Piperazine derivatives useful as CCR5 antagonists 有权
标题翻译：哌嗪衍生物可用作CCR5拮抗剂
公开(公告)号：US06391865B1
公开(公告)日：2002-05-21
申请号：US09562814
申请日：2000-05-01
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Eric Gilbert , Marc A. Labroli
IPC分类号： A01N5500
CPC分类号： A61K31/496 , A61K45/06 , C07D211/58 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用式5的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，萘基，芴基，二苯基甲基或任选取代的苯基 - R 4是氢或烷基; R 6是氢，烷基或链烯基; R 4是氢或烷基; R 3是氢，烷基或烷氧基烷基，公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

6. 发明授权

US06387930B1 Piperidine derivatives useful as CCR5 antagonists 有权
标题翻译：哌啶衍生物可用作CCR5拮抗剂
公开(公告)号：US06387930B1
公开(公告)日：2002-05-14
申请号：US09562815
申请日：2000-05-01
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin
IPC分类号： C07D40104
CPC分类号： C07D401/14 , C07D211/58 , C07D413/14 , C07D417/14
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein X is —C(R13)2—, —C(R13)(R19)—, —C(O)—, —O—, —NH—, —N(alkyl)—, R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用下式的CCR5拮抗剂或其药学上可接受的盐，其中X是-C（R 13）2 - ， - C（R 13）（R 19） - ， - C（O） - ， - O - N（烷基） - ，R是任选取代的苯基，吡啶基，噻吩基或萘基; R1是H，烷基或烯基; R2是任选取代的苯基，苯基烷基，杂芳基或杂芳基烷基，萘基，芴基或二苯基甲基; R 3是任选取代的苯基，杂芳基或萘基; R4是H，烷基，氟代烷基，环丙基甲基，-CH2CH2OH，-CH2CH2-O-烷基，-CH2C（O）-O-烷基，-CH2C（O）NH2，-CH2C（O）或-CH 2 C（O）-N（烷基）2; R 19是任选取代的苯基，杂芳基或萘基，环烷基，环烷基烷基或烷氧基烷基; 和R 5，R 13，R 14，R 15和R 16是氢或烷基，用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化以及新化合物，包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

7. 发明授权

US06132227A Receptacle assembly with improved enclosure 有权
标题翻译：插座组件具有改进的外壳
公开(公告)号：US06132227A
公开(公告)日：2000-10-17
申请号：US145801
申请日：1998-09-02
申请人： William C. Boteler , Michael W. Miller
发明人： William C. Boteler , Michael W. Miller
IPC分类号： H01R13/447 , H01R13/44
CPC分类号： H01R13/447
摘要： A receptacle assembly having a body and a hinged cover is provided to accept a plug with a threaded ring connector. The body has an open end, an exterior surface and a ridge formed on the exterior surface adjacent to the open end adapted to receive the threaded ring of the plug. The ridge of the body has at least one interruption and defines threads for engagement with the threaded ring on the plug. The hinged cover has an interior periphery and at least one protrusion formed on the interior periphery and alignable with the one interruption of the ridge and movable through the interruption and into an underlying position relative to the ridge such that the cover is securely fitted over the open end of and onto the body when the assembly is not in use by moving the cover toward the body followed by rotating the cover relative to the body. The ridge has at least one protrusion engagement portion defined by a side edge adjacent to and bounding one side of the one interruption, a lower edge extending in substantially perpendicular relation to the side edge and an inclined edge extending downwardly from the side edge to the lower edge such that the one protrusion is movable from an open position through the interruption down the inclined edge into the underlying position and into an increasingly secure position relative to the ridge to a closed sealed position against the lower edge. When the plug is removed from the receptacle, the cover automatically snaps shut over the open end of the body. The assembly further includes a compressible gasket mounted to and held loosely against an interior surface of the cover and is prevented from falling away from the cover by the one protrusion of the cover. The gasket is compressed as the one protrusion moves into the underlying position relative to the ridge of the body.
摘要翻译：提供具有主体和铰接盖的插座组件以接纳具有螺纹环连接器的插头。主体具有开口端，外表面和脊部，其形成在邻近开口端的外表面上，适于容纳塞子的螺纹环。主体的脊具有至少一个中断并且限定用于与插头上的螺纹环接合的螺纹。铰接盖具有内周边和至少一个凸起，该突起形成在内周上并与脊的一个中断对准，并且能够通过中断移动并且相对于凸脊进入下面的位置，使得盖牢固地配合在开口通过将盖朝向身体移动而不是使用组件而使盖相对于身体旋转而在身体的端部和上方。脊具有至少一个突出接合部分，该突起接合部分由邻近于并且限定一个中断部分的一侧的侧边缘限定，下边缘基本上垂直于侧边缘延伸，以及从侧边缘向下延伸的倾斜边缘使得所述一个突起能够从打开位置移动通过所述倾斜边缘的中心向下移动到下面的位置，并且相对于所述脊到相对于所述下边缘的封闭的密封位置处于越来越安全的位置。当插头从插座中取出时，盖子会自动关闭身体的开口端。组件还包括安装到并保持在盖的内表面上并被松动地保持在盖的内表面上的可压缩垫圈，并且通过盖的一个突起防止其从盖上脱落。当一个突起移动到相对于身体的脊的下方位置时，衬垫被压缩。

8. 发明申请

US20140057893A1 SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT 有权
标题翻译：取代的环状化合物，包含这些化合物的组合物和处理方法
公开(公告)号：US20140057893A1
公开(公告)日：2014-02-27
申请号：US14110332
申请日：2012-04-05
申请人： Scott Edmondson , Zhiqiang Guo , Harold B. Wood , Andrew W. Stamford , Michael W. Miller , Duane E. DeMong , Gregori J. Morriello , Rajan Anand , Vincent J. Colandrea , Megan Macala , Milana Maletic , Cheng Zhu , Yuping Zhu , Wanying Sun , Kake Zhao , Yong Huang , Joel M. Harris , Lehua Chang , Nam Fung Kar , Zhiyong Hu , Liping Wang , Bowei Wang , Ping Liu , Jason W. Szewczyk , William B. Geiss
发明人： Scott Edmondson , Zhiqiang Guo , Harold B. Wood , Andrew W. Stamford , Michael W. Miller , Duane E. DeMong , Gregori J. Morriello , Rajan Anand , Vincent J. Colandrea , Megan Macala , Milana Maletic , Cheng Zhu , Yuping Zhu , Wanying Sun , Kake Zhao , Yong Huang , Joel M. Harris , Lehua Chang , Nam Fung Kar , Zhiyong Hu , Liping Wang , Bowei Wang , Ping Liu , Jason W. Szewczyk , William B. Geiss
IPC分类号： C07D513/04 , C07D413/14 , C07D413/04 , C07D498/04 , C07D405/04 , C07D471/04 , C07D487/04 , C07D401/12 , C07D211/22
CPC分类号： C07D513/04 , A61K9/4858 , C07D211/22 , C07D401/12 , C07D405/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
摘要翻译：公开了取代的式I的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。该化合物可用作G蛋白偶联受体GPR-119的激动剂。还包括药物组合物和治疗方法

9. 发明申请

US20130072468A1 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS 审中-公开
标题翻译：取代的PIPERAZINES作为CB1拮抗剂
公开(公告)号：US20130072468A1
公开(公告)日：2013-03-21
申请号：US13616825
申请日：2012-09-14
申请人： Eric J. Gilbert , William J. Greenlee , Michael W. Miller , Jack D. Scott , Andrew W. Stamford
发明人： Eric J. Gilbert , William J. Greenlee , Michael W. Miller , Jack D. Scott , Andrew W. Stamford
IPC分类号： A61K31/496 , A61K31/495 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/06 , C07D413/06 , A61K31/5377 , C07D417/06 , A61K31/506 , C07D487/04 , A61K31/397 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/30 , A61P25/32 , A61P25/34 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P3/04 , A61P3/10 , A61P1/00 , A61P1/08 , A61P1/12 , A61P13/00 , A61P15/08 , A61P29/00 , A61P9/10 , A61P31/00 , A61P35/00 , A61P3/00 , A61P1/16 , A61P9/00 , C07D241/04
CPC分类号： C07D403/10 , C07D241/04 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D407/04 , C07D413/06 , C07D417/06 , C07D487/04
摘要： Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍和精神病，成瘾（例如吸烟停止），胃肠道疾病和心血管疾病。

10. 发明申请

US20130007792A1 RECOMMENDING MEDIA PROGRAMS BASED ON MEDIA PROGRAM POPULARITY 有权
标题翻译：基于媒体规划的推荐媒体规划
公开(公告)号：US20130007792A1
公开(公告)日：2013-01-03
申请号：US13613426
申请日：2012-09-13
申请人： Joon-Hee Jeon , Vincent Dureau , Steve Dale Benting , Zhenhai Lin , Michael W. Miller , Manish G. Patel
发明人： Joon-Hee Jeon , Vincent Dureau , Steve Dale Benting , Zhenhai Lin , Michael W. Miller , Manish G. Patel
IPC分类号： H04N21/24
CPC分类号： H04N21/4668 , G06F17/30017 , G06F17/30846 , H04N5/44543 , H04N21/251 , H04N21/252 , H04N21/254 , H04N21/25891 , H04N21/431 , H04N21/44222 , H04N21/4532 , H04N21/4667 , H04N21/4756 , H04N21/4826 , H04N21/4828
摘要： A computer-implemented method includes receiving information expressing a user's interest in one or more media programs, obtaining information indicative of popularity for a plurality of media programs responsive to the received information by individuals other than the user, and transmitting one or more recommendations of media programs for display to the user, from the plurality of media programs that relate to the received information.
摘要翻译：计算机实现的方法包括接收表示用户对一个或多个媒体节目的兴趣的信息，响应于除用户之外的个人接收到的信息，获得指示多个媒体节目的流行度的信息，以及传送一个或多个媒体推荐从与接收的信息相关的多个媒体节目向用户显示的节目。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式